Axsome Therapeutics, Inc. (NasdaqGM: AXSM)
Health Care · Pharmaceuticals · US
$206.90
-0.42% today · +75.3% 1Y
Axsome Therapeutics, Inc. (NasdaqGM: AXSM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $10.88B and employs 1,346 people.
Over the last twelve months the share price has gained 75.3%, trading between 109.40 and 260.19.
Tweenvest scores Axsome Therapeutics, Inc. across four factors: quality 35/100, value 75/100. Its strongest factor is value.
AXSM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $10.88B
- Revenue (TTM)
- $776.57M
- P/E
- —
- EPS
- -3.76
- Dividend yield
- —
- Beta (5Y)
- 0.73
- 52-week high
- $260.19
- 52-week low
- $109.40
- Avg volume (3M)
- —
- Shares outstanding
- 52.38M
- Employees
- 1,346
- Next earnings
- —
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
- ISIN
- US05464T1043
- Founded
- 2012
- Listed since
- Nov 19, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.16 | +0.34% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.18 | -0.24% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.30 | -1.41% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.00 | -1.14% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.23% |
Figures last refreshed Aug 18, 2026.